Literature DB >> 20345245

Molecular and cellular mechanisms of learning disabilities: a focus on NF1.

C Shilyansky1, Y S Lee, A J Silva.   

Abstract

Neurofibromatosis Type I (NF1) is a single-gene disorder characterized by a high incidence of complex cognitive symptoms, including learning disabilities, attention deficit disorder, executive function deficits, and motor coordination problems. Because the underlying genetic cause of this disorder is known, study of NF1 from a molecular, cellular, and systems perspective has provided mechanistic insights into the etiology of higher-order cognitive symptoms associated with the disease. In particular, studies of animal models of NF1 indicated that disruption of Ras regulation of inhibitory networks is critical to the etiology of cognitive deficits associated with NF1. Animal models of Nf1 identified mechanisms and pathways that are required for cognition, and represent an important complement to the complex neuropsychological literature on learning disabilities associated with this condition. Here, we review findings from NF1 animal models and human populations affected by NF1, highlighting areas of potential translation and discussing the implications and limitations of generalizing findings from this single-gene disease to idiopathic learning disabilities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345245      PMCID: PMC3063104          DOI: 10.1146/annurev-neuro-060909-153215

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  106 in total

Review 1.  Sensitive periods in the development of the brain and behavior.

Authors:  Eric I Knudsen
Journal:  J Cogn Neurosci       Date:  2004-10       Impact factor: 3.225

2.  Treatment of ADHD in neurofibromatosis type 1.

Authors:  Victor-F Mautner; Lan Kluwe; Sarang D Thakker; Robert A Leark
Journal:  Dev Med Child Neurol       Date:  2002-03       Impact factor: 5.449

Review 3.  Neurofibromatosis 1.

Authors:  Timothy M Lynch; David H Gutmann
Journal:  Neurol Clin       Date:  2002-08       Impact factor: 3.806

Review 4.  Noonan syndrome and related disorders: genetics and pathogenesis.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Annu Rev Genomics Hum Genet       Date:  2005       Impact factor: 8.929

5.  An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes.

Authors:  D F Easton; M A Ponder; S M Huson; B A Ponder
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

6.  Impact of neurofibromatosis type 1 on school performance.

Authors:  Lianne C Krab; Femke K Aarsen; Arja de Goede-Bolder; Coriene E Catsman-Berrevoets; Willem F Arts; Henriette A Moll; Ype Elgersma
Journal:  J Child Neurol       Date:  2008-09       Impact factor: 1.987

7.  Children and adolescents with neurofibromatosis 1: a behavioral phenotype.

Authors:  C V Dilts; J C Carey; J C Kircher; R O Hoffman; D Creel; K Ward; E Clark; C O Leonard
Journal:  J Dev Behav Pediatr       Date:  1996-08       Impact factor: 2.225

8.  Neurofibromin is required for barrel formation in the mouse somatosensory cortex.

Authors:  Mark E Lush; Yun Li; Chang-Hyuk Kwon; Jian Chen; Luis F Parada
Journal:  J Neurosci       Date:  2008-02-13       Impact factor: 6.167

9.  Regulation of the Ras-GTPase activating protein neurofibromin by C-tail phosphorylation: implications for protein kinase C/Ras/extracellular signal-regulated kinase 1/2 pathway signaling and neuronal differentiation.

Authors:  George Leondaritis; Loizos Petrikkos; Dimitra Mangoura
Journal:  J Neurochem       Date:  2009-02-11       Impact factor: 5.372

10.  Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.

Authors:  Toshiyuki Araki; Gordon Chan; Susan Newbigging; Lily Morikawa; Roderick T Bronson; Benjamin G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

View more
  39 in total

Review 1.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

Review 2.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

Review 3.  Understanding intellectual disability through RASopathies.

Authors:  Alvaro San Martín; Mario Rafael Pagani
Journal:  J Physiol Paris       Date:  2014-05-21

4.  Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials.

Authors:  Jonathan M Payne; Belinda Barton; E Arthur Shores; Kathryn N North
Journal:  J Neurol       Date:  2012-08-09       Impact factor: 4.849

Review 5.  The role of CELF proteins in neurological disorders.

Authors:  Jean-Marc Gallo; Carl Spickett
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

6.  Education, cognition, health knowledge, and health behavior.

Authors:  Naci Mocan; Duha T Altindag
Journal:  Eur J Health Econ       Date:  2013-04-02

Review 7.  Treatment of neurodevelopmental disorders in adulthood.

Authors:  Eero Castrén; Ype Elgersma; Lamberto Maffei; Randi Hagerman
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

Review 8.  Alternative splicing of the neurofibromatosis type I pre-mRNA.

Authors:  Victoria A Barron; Hua Lou
Journal:  Biosci Rep       Date:  2012-04-01       Impact factor: 3.840

9.  Another VCP interactor: NF is enough.

Authors:  Conrad C Weihl
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

10.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.

Authors:  Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.